U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,816.90
    -18.90 (-1.03%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,410.61
    +2,485.91 (+6.39%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Why Trump’s timeline for a coronavirus vaccine in 2020 is too optimistic: Harvard expert

·Senior Writer
·4 min read

President Trump doubled down on his optimism that researchers in the U.S. will be able to develop a vaccine for coronavirus by the end of the year in a virtual town hall with Fox News on Sunday, but that timeline is leaving some experts scratching their heads.

Echoing the timeline from Dr. Fauci, the White House’s own lead medical professional on the coronavirus task force who has guided to a longer timeline of 12 to 18 months to develop a vaccine, Harvard Medical School professor Dr. Mark Poznansky warned that the scientific unknowns surrounding the new virus likely dictate that the process will probably extend into 2021.

“The 12 to 18 months that we have been hearing from Dr. Fauci sort of makes sense,” Dr. Poznansky, who also serves as the Director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, told Yahoo Finance. “There are maybe areas of that that can be shortened, but the end of the year sounds aggressive at best.”

White House coronavirus response coordinator Dr. Deborah Birx listens as director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci speaks during a meeting between President Donald Trump and Gov. John Bel Edwards, D-La., about the coronavirus response, in the Oval Office of the White House, Wednesday, April 29, 2020, in Washington. (AP Photo/Evan Vucci)
White House coronavirus response coordinator Dr. Deborah Birx listens as director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci speaks during a meeting between President Donald Trump and Gov. John Bel Edwards, D-La., about the coronavirus response, in the Oval Office of the White House, Wednesday, April 29, 2020, in Washington. (AP Photo/Evan Vucci)

Mainly, Poznansky highlighted that while it would be possible to shave time off the development of a vaccine, it might not be safe to do so. Beyond that, because so little is currently known about the normal immune response to COVID-19, Poznansky posited that it could even take to the end of the year to have all those questions answered — let alone the process of building out and distributing the actual vaccine to humans.

“The devil is in the detail and no one wants to look at the detail,” he said. “The detail is, as of today, we don't yet know what a protective immune response to the virus is. So we're building a vaccine to generate a protective response that we don't quite yet know what it is. So whether that will be three months, six months or a year is the fundamental sort of biology of this that you almost can't get away from.”

Distribution of a vaccine

Philanthropists like Microsoft founder Bill Gates through his Gates Foundation have offered to help expedite production of a vaccine once the important unknowns are answered. But even then, as emergency physician and visiting professor at George Washington University School of Public Health Dr. Leana Wen told Yahoo Finance, it’s important to keep in mind that a vaccine for something that spreads as quickly as coronavirus is only truly useful once it’s widely distributed to the population.

“Even if we have a vaccine by the end of the year, that doesn't mean we'll have vaccinations,” she said. “I think that's really important because even if you have a drug approved and it's effective, it's only going to be effective if everybody is able to receive the vaccine. The idea of getting millions of doses, maybe billions produced by the end of the year and for us to have gone through the clinical trials, that seems like a pretty big stretch to me.”

To be fair, the Trump administration has fast tracked promising drug treatments during the outbreak — mainly shepherding the FDA’s approval of Gilead’s Remdesivir for use in patients with COVID-19. Similar exceptions could be made for a vaccine to expedite development, but Poznansky said that shouldn’t be used reliably in laying out a timeline.

“If some of those hurdles get removed that will make a difference, but at the moment I’d stick with the most likely time table of 12 to 18 months,” he said.

Zack Guzman is the host of YFi PM as well as a senior writer and on-air reporter covering entrepreneurship, cannabis, startups, and breaking news at Yahoo Finance. Follow him on Twitter @zGuz.

Read the latest financial and business news from Yahoo Finance

Read more:

Small US towns are neglected from coronavirus relief and it's a 'slap in the face': Georgia mayor

Coronavirus job losses hit these 10 states the hardest

The coronavirus just doubled the risk of mass bankruptcies

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, LinkedIn, YouTube, and reddit.